Drug Trial Radar · NCT07258251
Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach
Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
6,000
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- The Task Force for Global HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Phichit Provincial Public Health Office, Ministry of Public Health, Thailand (Host institution); Siriraj Hospital; Ministry of Health, Thailand; Phichit Provincial Hospital; Liver Foundation Thailand; Thai Association for the Study of the Liver
- First posted
- Dec 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study in Phichit province, Thailand, aims to find and support adults born before 1992 who are at high risk for hepatitis B infection. Many people in this group were born before the universal hepatitis B vaccine was available and may not know they are infected. The study will invite nearly 240,000 eligible adults for free hepatitis B screening. Those who test positive will be linked to care at one of 12 district hospitals. Doctors will use simplified 2024 World Health Organization (WHO) guidelines to decide who needs treatment. Eligible individuals will receive a safe, effective daily medicine (tenofovir alafenamide). The study will use community health volunteers and phone reminders to help patients stay in care and take their medication regularly. Over three years, the study will track improvements in liver health and virus levels, aiming to prevent liver cirrhosis and cancer.
Conditions
- Chronic Hepatitis B
- Hepatitis B Virus Infection
Interventions
Tenofovir Alafenamide (TAF)Drug
HBsAg-positive individuals meeting WHO 2024 treatment eligibility criteria will receive daily oral TAF. Tenofovir disoproxil fumarate (TDF) may be used if TAF is unavailable.
Community-Based SupportBehavioral
Interventions to improve linkage to care, retention, and treatment adherence. This includes telephone calls, home visits by community health volunteers, and phone/SMS reminders for appointments.
Simplified WHO 2024 CriteriaDiagnostic test
HBsAg-positive individuals will be evaluated for treatment eligibility using simplified 2024 WHO guidelines, including APRI score, as an alternative to HBV DNA testing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HBsAg Screening UptakeTime frame: 36 months
- Linkage to CareTime frame: 36 months
- Treatment InitiationTime frame: 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Phichit Provincial Hospital, Phichit / 12 District Hospitals in Phichit Province
Phichit, Changwat Phichit, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.